CNS depressants; refer to WARNINGS section for detailed guidance.
Source: NLP:amitriptyline hydrochloride
83 interactions on record
CNS depressants; refer to WARNINGS section for detailed guidance.
Source: NLP:amitriptyline hydrochloride
CNS-depressant action of clonazepam may be potentiated by barbiturates, increasing risk of sedation and respiratory depression.
Source: NLP:clonazepam
Actions of benzodiazepines may be potentiated by barbiturates.
Source: NLP:clorazepate dipotassium
Diazepam injection has produced hypotension or muscular weakness when used with barbiturates. May potentiate diazepam action.
Source: NLP:diazepam
Barbiturate administration causes folate deficiency through increased loss or metabolic interference.
Source: NLP:folic acid
Produces increased CNS-depressant effects including respiratory depression and sedation.
Source: NLP:lorazepam
May reduce contraceptive effectiveness and result in unintended pregnancy or breakthrough bleeding by increasing metabolism of contraceptive steroids.
Source: NLP:norethindrone
Promethazine increases sedative action; dose of barbiturates should be reduced by at least one-half.
Source: NLP:promethazine hydrochloride
Promethazine may increase, prolong, or intensify sedative action. Dose should be reduced by at least one-half when given concomitantly.
Source: NLP:promethazine hydrochloride and dextromethorphan hydrobromide
May increase anesthetic/sedative effects and cardiorespiratory depression; can result in pronounced decreases in blood pressure and cardiac output.
Source: NLP:propofol
Produces additive CNS-depressant effects when co-administered with temazepam.
Source: NLP:temazepam
Potentiation of orthostatic hypotension may occur when given concurrently with hydrochlorothiazide.
Source: NLP:amiloride hydrochloride and hydrochlorothiazide
Possibility of additive or potentiating effect with CNS depressants.
Source: NLP:apraclonidine
Atropine may potentiate the effect of barbiturates. Barbiturates should be used cautiously in treating convulsions from atropine exposure.
Source: NLP:atropine
Atropine may potentiate the effect of barbiturates. Barbiturates should be used cautiously in treating convulsions from atropine exposure.
Source: NLP:atropine sulfate injection usp, 0.5 mg/0.7 ml
Hepatic enzyme induction may enhance corticosteroid metabolism, requiring increased corticosteroid dosage.
Source: NLP:betamethasone sodium phosphate and betamethasone acetate
Possibility of additive or potentiating CNS depressant effect with brimonidine.
Source: NLP:brimonidine
CNS depressant with potential for additive or potentiating effect when used with brimonidine tartrate ophthalmic solution.
Source: NLP:brimonidine tartrate
CNS depressant with possibility of additive or potentiating effect on central nervous system depression.
Source: NLP:brimonidine tartrate and timolol maleate
Potentiation of orthostatic hypotension may occur with hydrochlorothiazide component.
Source: NLP:candesartan cilexetil and hydrochlorothiazide
Barbiturates may result in additive or potentiating CNS depressant effects with YUVEZZI.
Source: NLP:carbachol and brimonidine tartrate
Potentiation of orthostatic hypotension may occur when barbiturates are given concurrently with chlorothiazide.
Source: NLP:chlorothiazide
Potentiation of orthostatic hypotension may occur when barbiturates are given concurrently with chlorothiazide sodium.
Source: NLP:chlorothiazide sodium
Barbiturates decrease plasma levels of clomipramine.
Source: NLP:clomipramine hydrochloride
Barbiturates may decrease plasma levels of clomipramine; dosage adjustment may be needed.
Source: NLP:clomipramine hydrochloride capsules
Clonidine may potentiate the CNS-depressive effects of barbiturates.
Source: NLP:clonidine
Clonidine may potentiate the CNS-depressive effects of barbiturates.
Source: NLP:clonidine hydrochloride
Clonidine may potentiate CNS-depressive effects of barbiturates.
Source: NLP:clonidine transdermal system
Cyclobenzaprine may enhance the effects of barbiturates and CNS depression.
Source: NLP:cyclobenzaprine
Cyclobenzaprine may enhance CNS depressant effects of barbiturates.
Source: NLP:cyclobenzaprine hydrochloride
Barbiturates induce CYP3A4 enzyme activity, enhancing corticosteroid metabolism and requiring dose increases.
Source: NLP:depo-medrol, lidocaine, isopropyl alcohol
Similar association with reduced efficacy and breakthrough bleeding suggested, though less marked than with rifampin.
Source: NLP:desogestrel and ethinyl estradiol and ethinyl estradiol
CYP 3A4 inducers may enhance metabolism of dexamethasone, requiring dosage increase.
Source: NLP:dexamethasone
Barbiturates induce CYP 3A4 enzyme activity, enhancing dexamethasone metabolism and requiring dosage increase.
Source: NLP:dexamethasone 1.5 mg
Barbiturates induce CYP 3A4 and enhance dexamethasone metabolism, requiring dosage increase.
Source: NLP:dexamethasone intensol
May potentiate CNS depressant effects of diphenoxylate hydrochloride and atropine sulfate. Monitor for CNS adverse reactions.
Source: NLP:diphenoxylate hydrochloride and atropine sulfate
Barbiturates shorten the half-life of doxycycline, thereby lowering doxycycline concentration in the body.
Source: NLP:doxycycline
Barbiturates decrease the half-life of doxycycline.
Source: NLP:doxycycline hyclate
Additive or potentiating CNS depressant effects; droperidol dose should be reduced when used concomitantly.
Source: NLP:droperidol
Induce CYP3A4 enzyme, may decrease effectiveness of COCs or increase breakthrough bleeding.
Source: NLP:drospirenone and ethinyl estradiol
May decrease the effectiveness of hormonal contraceptives or increase breakthrough bleeding through CYP3A4 enzyme induction.
Source: NLP:drospirenone, ethinyl estradiol and levomefolate calcium and levomefolate calcium
Enzyme inducers that may decrease effectiveness of COCs or increase breakthrough bleeding. Use back-up contraception.
Source: NLP:drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
Potent CYP3A inducers expected to decrease estazolam concentrations; also produce CNS depression that may potentiate benzodiazepine action.
Source: NLP:estazolam
Similar association with reduced efficacy, though less marked than rifampin.
Source: NLP:ethynodiol diacetate and ethinyl estradiol
May decrease plasma concentrations of etonogestrel and diminish contraceptive effectiveness or increase breakthrough bleeding.
Source: NLP:etonogestrel
CYP3A4 enzyme inducer that may decrease plasma concentrations of etonogestrel and ethinyl estradiol, potentially diminishing contraceptive effectiveness or increasing breakthrough bleeding.
Source: NLP:etonogestrel and ethinyl estradiol
Increased metabolic clearance of fludrocortisone acetate due to hepatic enzyme induction. May require increased steroid dosage.
Source: NLP:fludrocortisone acetate
May reduce glucose-lowering effect of glimepiride, leading to worsening glycemic control.
Source: NLP:glimepiride
Barbiturates usually depress griseofulvin activity by decreasing plasma levels, requiring dosage adjustment of griseofulvin.
Source: NLP:griseofulvin
Potentiation of orthostatic hypotension may occur.
Source: NLP:hydrochlorothiazide
Barbiturates induce cytochrome P450 3A4 enzyme activity, enhancing corticosteroid metabolism and requiring increased corticosteroid dosage.
Source: NLP:hydrocortisone sodium succinate
Hepatic enzyme inducers that decrease imipramine plasma concentration. Dose adjustment of imipramine may be necessary.
Source: NLP:imipramine hydrochloride
CYP3A4 inducers that decrease ivabradine plasma concentrations. Avoid concomitant use.
Source: NLP:ivabradine
Barbiturates induce CYP3A4 and may decrease plasma concentrations of COCs, potentially diminishing contraceptive effectiveness or increasing breakthrough bleeding.
Source: NLP:levonorgestrel and ethinyl estradiol and ferrous bisglycinate
Barbiturates induce CYP3A4 enzymes, potentially decreasing contraceptive effectiveness and increasing breakthrough bleeding.
Source: NLP:norethindrone and ethinyl estradiol and ferrous fumarate
Enzyme inducers that may decrease plasma concentrations of contraceptive hormones and reduce effectiveness of hormonal contraceptives or increase breakthrough bleeding.
Source: NLP:levonorgestrel / ethinyl estradiol and ethinyl estradiol
Lofexidine may potentiate CNS depressant effects of barbiturates.
Source: NLP:lofexidine
Lofexidine may potentiate CNS depressant effects of barbiturates.
Source: NLP:lofexidine hydrochloride
Additive CNS depressant effects may occur; dosage adjustment needed when used concomitantly with magnesium sulfate.
Source: NLP:magnesium sulfate
Hepatic enzyme inducers may increase corticosteroid clearance.
Source: NLP:ammonia, lidocaine hydrochloride, triamcinolone acetonide, povidone-iodine
May decrease effectiveness of medroxyprogesterone acetate through enzyme induction. Counsel use of back-up or alternative contraception.
Source: NLP:medroxyprogesterone acetate
Barbiturates induce cytochrome P450 3A4 and may enhance corticosteroid metabolism, requiring dosage increase.
Source: NLP:methylprednisolone acetate
Hepatic enzyme inducers that enhance corticosteroid metabolism and may require increased corticosteroid dosage.
Source: NLP:methylprednisolone sodium succinate
Hypotensive effects may be potentiated by volume contraction associated with metolazone therapy.
Source: NLP:metolazone
Additive drowsiness and CNS depression reported with concurrent use. Caution advised.
Source: NLP:nabilone
Enzyme inducers that may decrease plasma concentrations of CHCs and potentially diminish effectiveness or increase breakthrough bleeding.
Source: NLP:norelgestromin and ethinyl estradiol
CYP3A4 inducer that may decrease the effectiveness of COCs or increase breakthrough bleeding.
Source: NLP:norethindrone acetate and ethinyl estradiol, and ferrous fumarate
Enzyme inducers that may decrease plasma concentrations of norethindrone and ethinyl estradiol, potentially diminishing contraceptive effectiveness or increasing breakthrough bleeding.
Source: NLP:norethindrone and ethinyl estradiol
CYP3A4 enzyme inducers that may decrease plasma concentrations of COCs and potentially diminish contraceptive effectiveness or increase breakthrough bleeding.
Source: NLP:norgestimate and ethinyl estradiol
CNS depressants that may increase CNS depression when used with FYCOMPA. Patients should limit activity until experienced with concomitant use.
Source: NLP:perampanel
Concomitant use with CNS depressants may potentiate CNS depression such as dizziness or cognitive adverse reactions.
Source: NLP:phentermine and topiramate extended-release
Barbiturates induce hepatic microsomal enzyme activity and enhance metabolism of prednisolone, requiring increased prednisolone dosage.
Source: NLP:prednisolone sodium phosphate
CYP 3A4 enzyme inducers enhance metabolism of corticosteroids, requiring increased prednisone dosage.
Source: NLP:prednisone
Promethazine may increase, prolong, or intensify sedative action; dose of barbiturates should be reduced by at least one-half.
Source: NLP:promethazine hydrochloride and phenylephrine hydrochloride
Protriptyline may enhance the effects of barbiturates.
Source: NLP:protriptyline hydrochloride
CYP3A4 and CYP2C8 inducers. Repaglinide dose increase and increased glucose monitoring may be required during concomitant use.
Source: NLP:repaglinide
Renal clearance of acidic drugs like barbiturates may be increased due to alkalinizing action of lactate.
Source: NLP:sodium chloride, sodium lactate, potassium chloride, calcium chloride
Potentiation of orthostatic hypotension may occur.
Source: NLP:spironolactone
Potentiation of orthostatic hypotension may occur.
Source: NLP:spironolactone and hydrochlorothiazide
Trazodone may enhance effects of barbiturates and other CNS depressants.
Source: NLP:trazodone hydrochloride
Hepatic enzyme inducers may increase corticosteroid clearance, reducing their effect.
Source: NLP:triamcinolone acetonide
CYP 3A4 inducers enhance metabolism of corticosteroids and may require dosage increase.
Source: NLP:triamcinolone acetonide extended-release injectable suspension
Sevoflurane administration is compatible with barbiturates and other commonly used intravenous anesthetics.
Source: NLP:sevoflurane